Sekisui acquires exclusive distribution rights of Qualigen’s FastPack IP System

2 August 2016 (Last Updated August 2nd, 2016 18:30)

US-based diagnostics company Sekisui has partnered with Qualigen to acquire the right of the exclusive worldwide distributor of the FastPack IP System.

US-based diagnostics company Sekisui has partnered with Qualigen to acquire the right of the exclusive worldwide distributor of the FastPack IP System.

FastPack IP is a patented, fully automated, compact and a quantitative immunoassay-based system. It uses monoclonal antibody technology in conjunction with a patented chemiluminescence substrate.

The FastPack IP System is Qualigen’s point-of-care system, which has been designed to offer quick and reliable results for multiple conditions such as Vitamin D, Testosterone, TSH, FT4, total and free PSA, and hCG.

It can generate complex immunoassay results in 12 minutes with a push of a button.

Sekisui Diagnostics president and COO Robert Schruender said: "Practice efficiency may be enhanced by performing these tests onsite, providing an effective way for physicians to offer their patients the convenience of receiving test results and implementation of therapy in a single visit."

The FastPack IP System is specifically suited for the physician office and features convenient reagent packs which make it an easy-to-use device in a clinical laboratory improvement amendments (CLIA) moderate complexity setting.

"Practice efficiency may be enhanced by performing these tests onsite."

It’s on demand results lead to reduced patient call-backs while increasing the physician office efficiencies.

The system offers the benefit of providing important blood test results in a single office visit thereby assisting physicians and practices improve both patient care and patient satisfaction.

The usage of the device does not require any specialised training.


Image: FastPack IP System. Photo: courtesy of PRNewsFoto / Sekisui Diagnostics.